Concomiitant use of dexibuprofen is not recommended with the following drugs because of drug - interactions Anticoagulants Lthium Other NSAIDs & aspirin

Symptomatic treatment of pain & infalmmation associated with osteoarthiritis

Common advese reactions were dyspepsia, diarrhea, fatigue, or drowsiness, headache, dizziness vertigo.

Peripheral odema GI adverse effects are less than that of ibuprofen and celocixib In long rtem study, adverse drug events were 15.2%

Racemic ibuprofen showed a 30% and diclofenac a 90% higher incidence of adverse reactions than dexibuprofen

Hypersensitivity to dexibuprofen to any other NSAID or to any of the excepients Active or suspected gastrointestiunal ulcer or history of recurrent gastrointestinal ulcer Gastrointestinal bleeding or other active bleedings or bleeding disorders.

Active Chrohns disease or active ulcerative colitis Severe heart failure Severe impaired hepatic function Haemorrhage diathesis & other coagulation disorders or patients receiving anticoagulant therapy Second trimester pregnancy

Precautions-

Administered with caution in patients with past history of serious cardiocascular thrombotic events, severe liver liver dysfunction, severe renal failure Patients with active or suspected gastrointestinal ulcer or history of recurrent gastrointestinal ulcer.

Elderly or debilated patients and in pregnancy

History of allergic rhibitis or bronchial asthma

Indication-

Symptomatic treatment of pain & infalmmation associated with osteoarthiritis

Dosage-

Maximum single dosage is 400mg dexibuprufen

Dose may be increased up to 1200 mg dexibuprofen per day in pts with acute conditions or exacerbations

Maximum daily dose is 1200mg In case of mild to moderate hepatic conditions

Pharmacology

Mechanism of action- Dexibuprofen inhibits prostagladin synthesis and formation of thromboxanes voia blockade of cytogenase (COX) enzymes. Dexibuprofen inhibits both COX-1 and COX-2 with somewhat lower potency for COX-2

Pharmacokinetics

Dexibuprofen is absorbed rapidly Reaches maximum concentrations of 12.4 microg/ml after 200mg respy. 12 microg/ml 400mg dose adjusted Time taken to reach maximum conc is tmax 2.1 to 2.2 hours Shows linear dose-relatonship Plasma protein binding is about 99%

Metablic transformation takes place in the liver (hydroxylation,carboxylation) Pharmacologically inactive metabolites are completely excreted mainly by the kidneys but also in bile.

The elimination half-life is 1.8- 3.5 hrs Admin of dexibuprofen with meal delays the time to reach max conc from 2.1 hours (after fasting conditions to 2.8 hours. After non-fasting conditions) and decreases the max plasma conc (from 20.6 to 18.1 ug/ml which is of no clinical relavance) but has no effect on the extent of absorption

Admin of dexibuprofen with meal delays the time to reach max conc from 2.1 hours (after fasting conditions to 2.8 hours fter non-fasting conditions) and decreases the max plasma conc (from 20.6 to 18.1 ug/ml which is of no clinical relavance) but has no effect on the extent of absorption

Pregnancy

Use of Dexiboprofen is not recommended in women attempting to conceive. No clinical data on exposed pregnancies are available for Dexibuprofen. The potential for human risk in pregnancy is unknown.

Lactation

Pharmacokinetics of Dexibuprofen has not been studied in lactating women and its administration is not recommended Children- Pharmacokinetics of Dexibuprofen has not been studied in peditric population and its administration is not recommended in pediatric patients

Elderly-

Pharmacokinetics of Dexibuprofen has not been studied in geriatric population and its administration is not recommended in Geriatric patients